Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Overview

Journal Dermatol Ther (Heidelb)

Date 2023 Nov 19

PMID 37981596

Authors

Shan Jing

Yang Lin

Randy Dockens

David Marchisin

Bing He

Ihab G Girgis

Anjaneya Chimalakonda

Bindu Murthy

Urvi Aras

Affiliations

Soon will be listed here.

Abstract

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects.

Methods: This phase I, double-blind, single-/multiple-dose study randomized healthy Chinese subjects 4:1 to a single dose of deucravacitinib 6 mg or placebo (group 1) or deucravacitinib 12 mg or placebo (group 2) on day 1; groups 1 and 2 received deucravacitinib 6 mg and 12 mg once daily, respectively, or placebo on days 5-19. Blood samples were collected on days 1-5 (0 predose-96 h postdose), day 5 (0-24 h postdose), days 9 and 12 (0 h), and day 19 (0-24 h postdose). Deucravacitinib and metabolite (BMT-153261, BMT-158170) concentrations were determined using liquid chromatography/mass spectrometry; pharmacokinetic parameters were calculated using noncompartmental analysis. Urine was collected on days 1-4 (4 h predose-96 h postdose). Safety was monitored throughout.

Results: Forty healthy Chinese subjects (groups 1 and 2: deucravacitinib, n = 32; placebo, n = 8) were enrolled. Deucravacitinib was rapidly absorbed after single-/multiple-dose administration, with median time to maximal plasma concentration of 1.5-2.3 h. Systemic exposure after single or multiple doses increased approximately twofold with twofold dose increase. Modest deucravacitinib accumulation was observed after multiple-dose administration (1.3- to 1.4-fold increase in area under the curve [AUC] under one dosing interval). Metabolite-to-parent ratios for maximal plasma concentration and AUC remained consistent in each dose group. Mean urinary percent recovery and renal clearance were similar between dose groups. Most adverse events (AEs) were mild/moderate, with no serious treatment-related AEs, deaths, or discontinuations due to AEs.

Conclusion: Deucravacitinib was safe and well tolerated in healthy Chinese subjects. Deucravacitinib exhibited rapid absorption, dose-related increases in exposure, comparable half-life, and no evidence of time-dependent pharmacokinetics, suggesting minimal effect of Chinese ethnicity on deucravacitinib pharmacokinetics.

Clinical Trial Registration: NCT03956953.

References

Burke J, Cheng L, Gillooly K, Strnad J, Zupa-Fernandez A, Catlett I . Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019; 11(502). DOI: 10.1126/scitranslmed.aaw1736. View

Winthrop K . The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017; 13(4):234-243. DOI: 10.1038/nrrheum.2017.23. View

Catlett I, Aras U, Hansen L, Liu Y, Bei D, Girgis I . First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2022; 16(1):151-164. PMC: 9841305. DOI: 10.1111/cts.13435. View

Bjornsson T, Wagner J, Donahue S, Harper D, Karim A, Khouri M . A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003; 43(9):943-67. DOI: 10.1177/0091270003256065. View

Eliasson E . Ethnicity and adverse drug reactions. BMJ. 2006; 332(7551):1163-4. PMC: 1463978. DOI: 10.1136/bmj.332.7551.1163. View

Baehr A, Pena J, Hu D . Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature. J Racial Ethn Health Disparities. 2016; 2(4):527-36. DOI: 10.1007/s40615-015-0101-3. View

Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P . Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018; 379(14):1313-1321. DOI: 10.1056/NEJMoa1806382. View

Mease P, Deodhar A, van der Heijde D, Behrens F, Kivitz A, Neal J . Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022; 81(6):815-822. PMC: 9120409. DOI: 10.1136/annrheumdis-2021-221664. View

Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaci D . Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022; 88(1):29-39. DOI: 10.1016/j.jaad.2022.07.002. View

10.

Strober B, Thaci D, Sofen H, Kircik L, Gordon K, Foley P . Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2022; 88(1):40-51. DOI: 10.1016/j.jaad.2022.08.061. View

11.

Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D . Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Basic Clin Pharmacol Toxicol. 2018; 123(3):294-300. DOI: 10.1111/bcpt.13001. View

12.

Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L . Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. J Clin Pharmacol. 2019; 59(12):1656-1668. PMC: 6852105. DOI: 10.1002/jcph.1473. View

13.

Zhuang Y, Calderon C, Marciniak Jr S, Bouman-Thio E, Szapary P, Yang T . First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016; 72(11):1303-1310. DOI: 10.1007/s00228-016-2110-5. View